Termination of Material Definitive Agreement. On June 23, 2026, Aytu BioPharma, Inc. (the “Company”) and Lannett Company, Inc. (together with its affiliates, “Lannett”) mutually agreed to terminate, effective as of June 23, 2026, that certain exclusive license agreement entered into by the parties on May 11, 2022, as amended on July 6, 2023, and July 17, 2025 (collectively, the “Metadate Agreement”). In connection with the termination of the Metadate Agreement, the Company entered into a Term…

Results of Operations and Financial Condition. On May 13, 2026, Aytu BioPharma, Inc. (the “Company”) issued a press release announcing its fiscal 2026 third quarter operational and financial results. As indicated in the press release, the Company scheduled a conference call and live audio webcast for May 13, 2026, at 4:30 p.m. Eastern time to discuss the operational and financial results and to answer questions. The conference call is publicly accessible via webcast and telephone (available l…

Entry into a Definitive Material Agreement . As previously disclosed, Aytu BioPharma, Inc. (the “Company”) completed public equity offerings in June 2023 and June 2025 whereby the Company issued certain warrants and prefunded warrants (collectively, the “Warrants”) to certain institutional investors (the “Investors”). In connection with the preparation of its Quarterly Reports on Form 10-Q for the quarters ended September 30, 2025, and December 31, 2025, the Company with consultation with its…

Material Modification to Rights of Security Holders . See the disclosures in

Results of Operations and Financial Condition. See the disclosures in

Unregistered Sales of Equity Securities . See the disclosures in

Results of Operations and Financial Condition. On February 3, 2026, Aytu BioPharma, Inc. (the “Company”) issued a press release announcing its fiscal 2026 second quarter operational and financial results. As indicated in the press release, the Company scheduled a conference call and live audio webcast for February 3, 2026, at 4:30 p.m. Eastern time to discuss the operational and financial results and to answer questions. The conference call is publicly accessible via webcast and telephone (av…

Results of Operations and Financial Condition. On November 13, 2025, Aytu BioPharma, Inc. (the “Company”) issued a press release announcing its fiscal 2026 first quarter operational and financial results. As indicated in the press release, the Company scheduled a conference call and live audio webcast for November 13, 2025, at 4:30 p.m. Eastern time to discuss the operational and financial results and to answer questions. The conference call is publicly accessible via webcast and telephone (a…

Results of Operations and Financial Condition. On September 23, 2025, Aytu BioPharma, Inc. (the “Company”) issued a press release announcing its fiscal 2025 full year and fourth quarter operational and financial results. As indicated in the press release, the Company scheduled a conference call and live audio webcast for September 23, 2025, at 4:30 p.m. Eastern time to discuss the operational and financial results and to answer questions. The conference call is publicly accessible via webcast…

Termination of Material Definitive Agreement. As previously disclosed in its United States Securities and Exchange Commission filings, Aytu BioPharma, Inc. (the “Company”) suspended its clinical development of AR101. In connection with this suspension, the Company has been engaged in negotiations with EnzCo, LLC (“EnzCo”) and Rumpus VEDS LLC, (“Rumpus VEDS”), Rumpus Therapeutics LLC, (“Rumpus Therapeutics”) and Rumpus Vascular LLC, (“Rumpus Vascular” and, together with Rumpus VEDS and Rumpus…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth under

Entry into a Material Definitive Agreement. On June 20, 2025, Aytu BioPharma, Inc. (“Aytu” or the “Company”) entered into an Amendment No. 6 to Loan and Security Agreement (the “Eclipse Amendment”), by and among the Company, Neos Therapeutics, Inc., Neos Therapeutics Brands, LLC, Neos Therapeutics, LP, Aytu Therapeutics, LLC, PharmaFab Texas, LLC and Cherry Creek Therapeutics, Inc. (collectively, the “Borrowers”), Eclipse Business Capital LLC (f/k/a Encina Business Credit, LLC), as agent, and…

Entry into a Material Definitive Agreement. On June 5, 2025, Aytu BioPharma, Inc. (the “Company” or “Aytu”), entered into an Exclusive Commercialization Agreement (the “Agreement”) with Fabre-Kramer Holdings, Inc. (“Fabre-Kramer”), pursuant to which the Company acquired certain rights and obligations in connection with the commercialization of EXXUA™ (gepirone) extended release tablets, an FDA-approved pharmaceutical indicated for the treatment of Major Depressive Disorder (MDD) in adults, in…

Entry into a Material Definitive Agreement. On June 5, 2025, Aytu BioPharma, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Lake Street Capital Markets, LLC, as underwriter (the “Underwriter”), relating to the public offering of 1,366,668 shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), at a purchase price per share of Common Stock of $1.50 (the “Offering Price”), and 8,233,332 prefunded warrants in lieu of Co…

Completion of Acquisition or Disposition of Assets. The information set forth under

The excerpt is incomplete and does not provide sufficient information to determine the nature of the event.

Results of Operations and Financial Condition. On May 14, 2025, Aytu BioPharma, Inc. (the “Company” or “Aytu”) issued a press release announcing its fiscal 2025 third quarter operational and financial results. As indicated in the press release, the Company scheduled a conference call and live audio webcast for May 14, 2025, at 4:30 p.m. Eastern time to discuss the operational and financial results and to answer questions. The conference call is publicly accessible via webcast and telephone (a…

Results of Operations and Financial Condition. On February 12, 2025, Aytu BioPharma, Inc. (the “Company” or “Aytu”) issued a press release announcing its fiscal 2025 second quarter operational and financial results. As indicated in the press release, the Company scheduled a conference call and live audio webcast for February 12, 2025, at 4:30 p.m. Eastern time to discuss the operational and financial results and to answer questions. The conference call is publicly accessible via webcast and t…

Results of Operations and Financial Condition. On November 13, 2024, Aytu BioPharma, Inc. (the “ Company ” or “ Aytu ”) issued a press release announcing its fiscal 2025 first quarter operational and financial results. As indicated in the press release, the Company scheduled a conference call and live audio webcast for November 13, 2024, at 4:30 p.m. Eastern time to discuss the operational and financial results and to answer questions. The conference call is publicly accessible via webcast an…

Chief Financial Officer — Mark K. Oki: The CFO was terminated and a new CFO was appointed.

Regulation FD Disclosure. On October 1, 2024, Aytu issued a press release titled “Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT® and Cotempla XR-ODT® in Canada.” A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (…

Results of Operations and Financial Condition. On September 26, 2024, Aytu BioPharma, Inc. (the “Company”) issued a press release announcing its fiscal 2024 full year and fourth quarter operational and financial results. As indicated in the press release, the Company scheduled a conference call and live audio webcast for September 26, 2024, at 4:30 p.m. Eastern time to discuss the operational and financial results and to answer questions. The conference call is publicly accessible via webcast…

Regulation FD Disclosure. On August 6, 2024, Aytu issued a press release titled “Aytu BioPharma Announces Sale of Consumer Health Business Following Wind Down of Consumer Health Operations.” A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth under

Entry into a Material Definitive Agreement. On June 12, 2024, Aytu BioPharma, Inc. (“ Aytu ” or the “ Company ”) entered into a Consent, Joinder and Amendment No. 5 to Loan and Security Agreement (the “ Eclipse Consent, Joinder and Amendment ”), by and among the Company, Neos Therapeutics, Inc., Neos Therapeutics Brands, LLC, Neos Therapeutics, LP, Aytu Therapeutics, LLC, PharmaFab Texas, LLC and Cherry Creek Therapeutics, Inc. (collectively, the “ Borrowers ”), Innovus Pharmaceuticals, Inc.,…